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OBJECTIVE – Beta-blockers remain important for secondary prevention after 
myocardial infarction (MI). Despite clinical guideline recommendations, the potential for 
poor glycemic control and masking warning signs of hypoglycemia limit their utilization 
in type 2 diabetes. This study evaluated factors predicting post-MI beta-blocker initiation 
among type 2 diabetic patients. 
RESEARCH DESIGN AND METHODS – A retrospective cohort of employed, 
commercially insured individuals was developed using de-identified enrollment files, 
medical claims, and pharmacy claims from 2007-2009 in the U.S. Inclusion criteria: (1) 
type 2 diabetes, (2) ≥18 years old, (3) continuous eligibility, (4) MI. Exclusion criteria: 
(1) females prescribed metformin exclusively without diabetes diagnosis, (2) <6 months 
eligibility pre-MI, (3) MI before diabetes identified, (4) pre-MI beta-blocker,  (5) receipt 
of sotalol post-MI, (6) no prescription claims, (7) <30 days between discharge and study 
end. Multivariable logistic regression with manual backward elimination was used to 
evaluate predictors of beta-blocker initiation. 
RESULTS – Of 341 type 2 diabetic patients, only 167 (49.0%) initiated beta-blockers 
within 30 days of discharge. Patients on a calcium channel blocker (ORadj: 2.63) and 
patients taking 1 to 5 medications (ORadj: 3.59) were more likely to initiate beta-blockers 
post-MI. Patients with heart failure (ORadj: 0.45) or an arrhythmia (ORadj: 0.44) were less 
likely to initiate beta-blockers as well as patients with renal failure who are not taking a 
diuretic (ORadj: 0.17). 
CONCLUSIONS – Although these results might not apply to older populations, they 
support the need for further investigation to determine whether more patients with type 2 
diabetes could benefit from beta-blocker treatment post-MI. 
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Existing evidence on the effect of beta-blockers in decreasing myocardial 
ischemia, re-infarction, and the frequency of complex ventricular dysrhythmias as well as 
increasing long-term survival supports the key role these drugs play in secondary 
prevention after myocardial infarction (MI).
1
 In fact, current guidelines for cardiovascular 
secondary prevention recommend initiation of oral beta-blockers within 24 hours of a 
MI;
1,2
 furthermore, in patients with an ST-elevation MI (STEMI), this therapy is 
recommended for 3 years post-MI.
2
 
However, beta-blockers have a history of relative contraindication in diabetic 
patients based on their potential to mask the warning signs of hypoglycemia
3-7
 and 
negatively impact glycemic control through beta-3 adrenergic receptor blockade on 
adipocytes.
5,7-10
 These effects are potentially more likely for nonselective beta-blockers. 
This brings about somewhat of a paradox. Patients with type 2 diabetes typically have 
worse cardiovascular outcomes after MI,
7
 suggesting they may have more to gain from 
beta-blocker therapy for secondary prevention. However, cardiovascular outcomes in 
diabetic patients are often improved through tight glycemic control,
9
 which may be 
worsened by beta-blocker therapy. There is also evidence that beta-blockers restore 
sympathovagal balance in diabetic patients with neuropathy and may also decrease the 
use of fatty acids in the myocardium, thereby decreasing oxygen demand.
4
  
Although current guidelines from the American Diabetes Association (ADA) 
recommend the use of beta-blockers in type 2 diabetic patients after a MI,
11,12
 few studies 
have formally evaluated the use of beta-blockers in this population.
3,13-17
 One 
observational study from Canada in the 1990s found that approximately 43% of type 2 
diabetic patients without previous exposure received beta-blockers after a MI.
3
 Other 
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studies have also found low rates of beta-blocker utilization among patients with type 2 
diabetes when compared to patients without diabetes.
14,15
 Patients taking other 
medications with an elevated risk of hypoglycemia (e.g. insulin and sulfonylureas) may 
be even less likely to be prescribed beta-blockers after a MI.
15
   
Few studies have evaluated beta-blocker utilization among patients with type 2 
diabetes after a MI in the United States.
15,16
 While clinical guidelines are relatively 
straightforward in this population, it is important to understand why real-world practice 
deviates from these recommendations so often. The purpose of this study was to 
determine the clinical and socioeconomic characteristics of type 2 diabetic patients that 
predict initiation of a beta-blocker to identify which patients are more or less likely to 
receive beta-blockers after MI. These predictors would provide useful knowledge of 
potential confounders to include in the evaluation of outcomes related to beta-blocker 
therapy. Also, clinicians and policymakers could potentially utilize this information to 
help develop interventions to improve the rate beta-blocker initiation in a post-MI setting 
if the treatment benefits are indeed significant for type 2 diabetic patients.  
 
Research Design and Methods 
Settings and databases 
This study was conducted using secondary claims data from a population of 
employed, commercially insured individuals with dependents from January 2007 through 
December 2009. From this data, a retrospective cohort was developed to evaluate 
predictors of new users of beta-blockers among type 2 diabetic patients after discharge 
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from hospitalization due to MI. The de-identified dataset included information on patient 
enrollment files, medical claims, and pharmacy claims. 
The following inclusion criteria were used to identify patients with type 2 diabetes 
post-MI: (1) diabetes identified through the first instance of ICD-9 codes for type 2 
diabetes in medical claims or prescription claims for oral diabetes medications identified 
through National Drug Codes (NDCs), (2) patients who were at least 18 years of age, (3) 
continuous eligibility through the entire study period, and (4) MI identified through ICD-
9 codes (all codes of the form 410.X1 as the primary or secondary diagnosis only). If a 
patient had multiple MIs during the study period, the first episode was considered the 
index MI. 
Exclusion criteria included the following: (1) females with no type 2 diabetes 
diagnosis and receiving metformin as the exclusive oral diabetes medication, (2) less than 
6 months of eligibility prior to first MI identified, (3) MI identified in claims before 
diabetes was identified, (4) receipt of a beta-blocker in prescription claims in the 6 
months prior to index MI, (5) receipt of sotalol as the first beta-blocker after MI, (6) no 
prescription claims for the duration of the study, and (7) less than 30 days between index 
discharge date and the end of the study. Female patients having no ICD-9 diagnosis for 
diabetes and receiving only metformin were excluded to prevent misclassification of 
patients with polycystic ovary syndrome as patients with diabetes. Patients receiving the 
beta-blocker sotalol after MI were excluded as this medication is indicated for the 
treatment of arrhythmias and is not indicated for secondary prevention of MI. See Figure 
1 for a flowchart depicting study design and cohort selection. 
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Predictors of beta-blocker initiation 
Predictors of beta-blocker receipt were demographic and clinical characteristics as 
well as measures of health care utilization. Demographic characteristics investigated 
include age, sex, race, and proxy measures of socioeconomic status including education, 
annual household income, and geographic region of residence. Clinical characteristics 
included both comorbidities and other medications the patient was taking prior to MI. 
Comorbidities were identified through the Elixhauser Comorbidity algorithm for the 6 
months preceding MI
18
 (see Table 1 for a full list of comorbidities). Patients taking 
insulin or insulin secretagogues (sulfonylureas and meglitinides) 90 days before index MI 
were identified, as these patients are likely at a higher risk of hypoglycemia. 
Additionally, patients taking any diabetes medication including insulin 90 days prior to 
index MI were identified. Patients taking other medications that could lower blood 
pressure were identified (see Table 1 for a full list of antihypertensive medication 
classes). Statin users were also identified to see if patients already taking post-MI 
recommended therapy were more likely to initiate beta-blockers. 
Number of prescription medications filled in the 90 days before index MI was 
used as a measure of health care utilization. The American Hospital Formulary Service 
(AHFS) Drug Information code was used to identify unique classes of medication. NDCs 
are linked to the AHFS codes to group unique drug products into drug classes. 
Prescription claims with no AHFS code or that were coded as unknown were not 
included in this count. Additionally, AHFS codes for medical products such as glucagon 
emergency kits (682212), lancets and other insulin testing sharps (940000), and insulin 
testing strips (362600) were not included in this count. All other unique AHFS codes 
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were included in the number of prescription medications received in the 90 days before 
index MI. Additionally, patients with a prescription fill for insulin testing strips 90 days 
prior to MI were identified as patients who were currently testing their blood glucose. 
Some clinicians have stated that diabetic patients who self-monitor blood glucose may be 
better candidates for beta-blocker therapy after MI.
7
 
Outcome 
The primary outcome of interest was receipt of a beta-blocker as identified in 
prescription claims within 30 days after hospital discharge. Beta-blockers were identified 
using the AHFS code 242400; this includes all beta-blockers and all combination 
medications with a beta-blocker in it. Patients who initiated beta-blockers within 30 days 
of hospital discharge were considered new users of beta-blockers. All other patients were 
identified as non-users. As stated previously, patients with previous beta-blocker 
exposure greater than 6 months before index MI were kept in the cohort to prevent 
selection bias; these patients were defined as new users versus non-users based solely on 
having a prescription claim for a beta-blocker after index hospital discharge.  
Statistical analysis 
Baseline demographic, clinical, and health care utilization characteristics were 
summarized for the entire population. Age was the only continuous variable and was 
evaluated using mean ± standard deviation (SD). Categorical variables were summarized 
using number (%) of patients with the given characteristic. 
Unadjusted bivariable statistics were used to compare new users to non-users of 
beta-blockers after MI among type 2 diabetic patients. A 2-sample t-test was used to 
compare the age of new users and non-users. For all other variables, a chi-square test (or 
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Fisher’s exact test where appropriate) was used to compare new users to non-users (α = 
0.05 for all bivariable analyses).  
Descriptive statistics for the first prescription fill of beta-blockers among new 
users were also summarized including copay, beta-blocker agent used, and 
pharmacologic properties of beta-blocker used. Pharmacologic properties include 
cardioselective versus nonselective beta-blockers, beta-blockers with intrinsic 
sympathomimetic activity (ISA), and beta-blockers with auxiliary mechanisms of action 
such as alpha-antagonism and nitric oxide-dependent vasodilation. 
A multivariable logistic regression model was utilized to predict new users and 
non-users of beta-blockers among type 2 diabetic patients after MI. The one patient 
(0.3%) with a missing value for race was added to the “Other” category, and missing 
values for education (N = 8; 2.3%) and income (N = 21; 6.2%) were replaced with the 
mode to allow patient inclusion in the regression analysis. Variables to be included in the 
initial regression model as predictors of receipt or non-receipt of beta-blockers were 
identified based on a combination of statistical significance in the bivariable analyses, 
identification in the literature, and clinical judgment (see Table 3 for a list of variables 
included in the initial model). Manual backward elimination was used to identify the best 
model using the Akaike information criterion (AIC) for model selection; variables with 
the highest P value were removed until the model with the minimum AIC value was 
identified. After model reduction, variables remaining in the model were evaluated for 
interactions using a similar manual backward elimination approach. Interactions to be 
included in the final model reduction were selected based on identification in the 
literature and clinical judgment. Adjusted odds ratios (ORadj) with 95% confidence 
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intervals (CI) were reported for all variables included in the final model. Internal 
validation of the final predictive model was completed using leave-one-out cross-
validation. All statistical analyses were completed using SAS
®
 software (Version 9.4 of 
the SAS System for Windows, Copyright © 2002-2012, SAS Institute, Cary, NC).  
 
Results 
Description of study cohort 
 Out of 396,619 patients who were identified as having type 2 diabetes, 743 
patients (about 1.9 out of 1,000 patients) had a MI during the 2007-2009 study period 
(Figure 1). Of these patients, 334 (45.0%) had a prescription claim for a beta-blocker 
within the 6 months before their index MI. After excluding patients with no prescription 
claims for the entire study period and patients discharged within 30 days of study end, 
341 patients were included in the study cohort. Of these patients, 48 (14.1%) had 
previous exposure to a beta-blocker outside of the 6-month pre-MI window. When these 
patients were compared to the rest of the cohort, there was no significant difference in the 
rate of beta-blocker initiation after hospital discharge (unadjusted OR: 0.86; P = 0.639). 
 The mean age of the cohort was 63.3 years (Table 1). Most patients were white 
(76.2%) and 58.4% of patients were male. Only 64 patients (19.2% of those reporting) 
had received a college degree including an associate degree or higher. Self-reported 
annual household income was categorized based on the distribution of values in the 
cohort. Among patients who reported income, about half (54.1%) reported annual 
household incomes in the $30,000 to $74,999 range while 17.5% and 28.4% of patients 
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belonged to the lower and higher income brackets, respectively. A large proportion of 
patients (56.0%) resided in the South based on U.S. Census geographic regions. 
 The most common comorbidities identified among the cohort prior to the index 
MI (Table 1) were hypertension (66.9%), cardiac arrhythmia (21.7%), chronic pulmonary 
disease (21.4%), congestive heart failure (16.1%), and peripheral vascular disorder 
(15.0%). Polypharmacy was identified as having prescription claims for 6 or more AHFS 
classes of medications within 90 days prior to index MI; 156 (45.8%) of patients fell into 
this category while 62 (18.2%) and 123 (36.1%) patients had either no medications or 1 
to 5 medications prior to MI, respectively. Only 165 (48.4%) had a prescription claim for 
a diabetes medication in the 90 days prior to index MI. Among these patients, 69 (20.2%) 
had a claim for insulin and 63 (18.5%) had a claim for either a sulfonylurea or a 
meglitinide. Only 67 (19.7%) of all cohort patients had an identified claim for blood 
glucose testing strips. The most common antihypertensive medications were ACE 
inhibitors and ARBs (111 patients; 32.6%) and diuretics (77 patients; 22.6%). Only 31 
patients (9.1%) were on a calcium channel blocker. There were 130 patients (38.1%) who 
received a statin in the 90 days prior to MI. Among the final cohort, 167 patients (49.0%) 
were identified as new users of beta-blockers while 174 patients (51.0%) were identified 
as non-users. 
Bivariable analyses 
 New users (61.1 ± 11.1) were younger than non-users (65.3 ± 14.5; P = 0.003) of 
beta-blockers post-MI (Table 2). Male patients were more likely to receive a beta-blocker 
after MI with an unadjusted OR of 1.67 (P = 0.021). Among new users, 78.9% and 4.8% 
of patients were white and black, respectively, compared to 73.6% and 10.9% in the non-
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users group (P = 0.115). In the unadjusted bivariable analyses, patients with congestive 
heart failure (OR: 0.33; P < 0.001), cardiac arrhythmia (OR: 0.39; P = 0.001), chronic 
pulmonary disease (OR: 0.58; P = 0.041), renal failure (OR: 0.35; P = 0.004), and fluid 
and electrolyte disorder (OR: 0.32; P = 0.001) were less likely to receive a beta-blocker 
within 30 days of MI hospital discharge. When comparing new users to non-users, there 
was no difference among patients with hypothyroidism (11.4% and 17.2%, respectively; 
P = 0.123). There was a significant difference when comparing number of medication 
classes being utilized prior to MI between new users and non-users of beta-blockers (P < 
0.001). Among new users, 53.3% of patients were taking a diabetes medication prior to 
index MI compared to 43.7% among non-users (P = 0.076). Patients taking an ACE 
inhibitor or ARB (OR: 1.68; P = 0.026), a calcium channel blocker (OR: 2.36; P = 
0.028), or a diuretic (OR: 2.02; P = 0.008) were more likely to receive a beta-blocker 
after hospital discharge as well. 
 Among the 167 new users in the cohort, the distribution of first beta-blockers 
utilized follows: 75 patients (44.9%) received metoprolol tartrate, 33 (19.8%) received 
metoprolol succinate, 51 (30.5%) received carvedilol, and 8 patients (4.8%) received 
either atenolol, nebivolol, or propranolol. All of these beta-blockers were cardioselective 
except carvedilol (which also has an ancillary alpha-1 antagonism mechanism of action) 
and propranolol. None of these beta-blockers had intrinsic sympathomimetic activity 
(ISA). 
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Multivariable logistic regression model 
 All variables from Table 2 were considered for inclusion in the initial 
multivariable logistic regression model. The comorbidities of pulmonary circulation 
disorder, liver disease, and obesity were excluded from the initial model because so few 
patients had these conditions. Additionally, obesity is often not well captured by ICD-9 
codes. The antihypertensive classes of vasodilator and other antiadrenergics were 
combined into one category for inclusion in the model. Due to issues of multicollinearity, 
it was decided to include only one measure of socioeconomic status in the initial 
regression model, either college degree or annual income. Whether education or income 
was included in the initial model, the same final model resulted. The initial model that 
included income was utilized to fit the model.  
 The initial multivariable regression model had an AIC of 445.559. After model 
reduction, the AIC decreased to 421.235 and included the following variables: age, sex, 
race, congestive heart failure, cardiac arrhythmia, renal failure, depression, fluid and 
electrolyte disorder, number of medications, calcium channel blocker, and diuretic. Other 
race compared to white (ORadj: 0.74; CI: 0.38–1.45) was not associated with receipt of a 
beta-blocker after a MI. However, black patients (ORadj: 0.37; CI: 0.14–0.99) were less 
likely to receive a beta-blocker compared to white patients; therefore, the race variable 
was changed to indicate whether the patient was black for further model reductions. 
 Interactions to investigate in the regression model were based on clinical 
knowledge and included (1) age with number of medications, (2) race with calcium 
channel blocker use, (3) congestive heart failure with fluid and electrolyte disorder, (4) 
congestive heart failure with diuretic use, (5) cardiac arrhythmia with calcium channel 
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blocker use, (6) renal failure with diuretic use, and (7) depression with number of 
medications. With the addition of these interaction terms, the AIC was 426.758. The final 
reduced model had an AIC of 416.904.  
The final reduced multivariable regression model including interaction terms can 
be seen in Table 3. Patients taking 1 to 5 medications prior to index MI (ORadj: 3.59; CI: 
1.74–7.38) were significantly more likely to receive a beta-blocker within 30 days post-
hospital discharge when compared to patients taking no medications; patients taking 
calcium channel blockers before index MI were also more likely to receive a beta-blocker 
after hospital discharge (ORadj: 2.63; CI: 1.05–6.60). Patients with congestive heart 
failure (ORadj: 0.45; CI: 0.21–0.96) or a cardiac arrhythmia (ORadj: 0.44; CI: 0.23–0.86) 
were less likely to initiate beta-blocker therapy post-MI. Among patients who were not 
taking a diuretic prior to index MI, patients with renal failure were less likely to initiate 
beta-blocker therapy as well (ORadj: 0.17; CI: 0.05–0.65); this association was not seen 
among patients with renal failure who were taking a diuretic (ORadj: 1.42; CI: 0.35–5.86). 
The c-statistic for the final fitted regression model was 0.767 (CI: 0.717–0.816). Using 
the leave-one-out cross-validation method, the c-statistic was reported as 0.719 (CI: 
0.665–0.773). 
Four sensitivity analyses were run to determine if imputation of missing values 
significantly impacted the final model. As education and income were the first variables 
eliminated in their respective models, the first two sensitivity analyses were conducted by 
excluding patients with missing values for education and income, respectively. In these 
two models, all point estimates had less than 10% relative change except fluid and 
electrolyte disorder and polypharmacy decreased 12.5% and 10.3%, respectively, in the 
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education model and congestive heart failure increased 11.1% in the income model. Two 
other sensitivity analyses were conducted by excluding the one patient with a missing 
value for race and changing the value of race to black. In the first sensitivity analysis, all 
point estimates had less than 10% relative change except renal failure among patients 
taking diuretics decreased 12.7%. When the race for that single patient was changed to 
black, no significant relative changes in point estimates occurred except a 13.6% increase 
in the black variable. The c-statistic changed less than 1% in all four sensitivity analyses.   
 
Conclusions 
 Despite recommendations from clinical guidelines, beta-blocker treatment 
continues to be underutilized in type 2 diabetic patients in the setting of secondary MI 
prevention. Only 49.0% of 341 patients in this study had a beta-blocker prescription 
claim within 30 days after their hospital discharge; this is similar to rates of beta-blocker 
treatment in this population previously reported.
3
 Even in this relatively young post-MI 
population, age was an important factor in bivariable analyses and was included in the 
final model. Age was trending towards significance in the final regression model, 
signifying that power may not have been met. Similarly, the best-fit model had sex in it 
although it was not significant; male patients may have been found to be more likely to 
initiate beta-blocker therapy in this setting if the cohort had been larger. Race also 
appeared to be a significant predictor of initiating beta-blocker therapy in this population 
until interaction terms were added to the model; it is possible that power was not met due 
to the low number of non-white patients in our cohort. Black patients with type 2 diabetes 
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may be significantly less likely to initiate beta-blocker therapy after MI, and this 
association should be further evaluated in a more diverse population. 
The strongest predictor of initiating beta-blocker therapy was number of 
medications filled within the 90 days prior to index MI; however, patients filling 6 or 
more medications in this period were no more likely to initiate a beta-blocker than 
patients taking no medications. It is not surprising that patients with a chronic condition 
such as diabetes who were taking no medications previously would be less likely to 
initiate a new preventative therapy. However, it is not clear why patients with no 
medications had similar rates of initiation compared to patients with 6 or more 
medications. Polypharmacy may be related to pill burden and patients not wanting to 
initiate a new therapy; it could also be related to drug interactions and safety concerns 
associated with the initiation of a beta-blocker. Patients taking a calcium channel blocker 
prior to MI were also more likely to initiate beta-blocker therapy. This may be related to 
patient behavior because the percent of patients taking other preventative therapies was 
higher in the new users group for all medications except vasodilators in the bivariable 
analyses. 
Patients with a history of cardiac arrhythmia were less likely to initiate therapy. 
This could be related to the antiarrhythmic effects of beta-blockers and the potential to 
worsen this comorbidity with the addition of a beta-blocker if the patient was already 
controlled on another antiarrhythmic medication. The use of diuretics may have served as 
a proxy for the severity of renal failure in the interaction within our model as diuretics are 
typically not recommended in patients with severe renal failure. While renal insufficiency 
is an important consideration for many drug therapies, this finding is interesting given 
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that most beta-blockers, including metoprolol and carvedilol, are not significantly 
eliminated in the urine before hepatic metabolism. Among patients not taking diuretics 
prior to index MI, renal failure patients were significantly less likely to initiate beta-
blocker therapy. This association was not present when considering patients who were 
taking a diuretic prior to index MI. It is interesting to note that although not always 
statistically significant, new users had smaller percentages of patients among all 
comorbidities except pulmonary circulation disorder and liver disease in the bivariable 
analyses. This again seems to align with the healthy user phenomenon. 
 This study confirms previous findings that beta-blockers are underutilized among 
patients with type 2 diabetes for secondary prevention of MI
3,14,15
 despite current 
recommendations.
1,2,11
 Male patients have also been shown to be more likely than 
females to receive beta-blockers among this population.
3
 To our knowledge, this is the 
only observational study that has evaluated initiation of beta-blocker therapy in this 
population while adjusting for other medication therapy, including number and classes of 
medication. This is also the only study to investigate beta-blocker initiation in a type 2 
diabetes post-MI population with a mean age less than 65. 
 Some limitations exist in our study. First, lab values were not available for a 
majority of patients near the time of hospital discharge. This is a common limitation in 
studies utilizing administrative claims data. Clinical decisions in diabetic patients rely 
heavily on glycemic control and this information may have provided added predictive 
value for our model. Secondly, our study could not account for prescriptions filled 
outside of coverage. The trend of marketing out-of-pocket low-cost prescription 
medications began in 2006 and included both metoprolol and carvedilol by the end of 
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2007.
19
 This creates a potential for misclassification bias. However, among the 167 new 
users of beta-blockers in our study, 7.8, 22.8, and 69.5% of patients had a co-pay of $0, 
between $0 and $4, and more than $4, respectively, when standardized to a 30-day 
supply. When these co-pay categories were stratified by income, 60.9, 65.5, and 79.2% of 
patients were paying more than $4 for a 30-day supply of a beta-blocker in the low-, 
middle-, and high-income categories, respectively. With such a high proportion of 
patients paying more than $4 per 30-day supply for a beta-blocker, $4 prescriptions may 
not have affected the behavior of patients with prescription insurance. In addition, 
excluding patients with no prescription claims in the entire study period may keep some 
of these patients out of the study population. Finally, we were not able to detect if 
patients were non-users because they were not prescribed a beta-blocker or because they 
chose not to fill a prescription they received after hospital discharge. Identifying whether 
patients received beta-blocker treatment is more important than why they did or did not 
receive the medication when evaluating outcomes related to this treatment; however, if 
post-MI beta-blocker therapy in patients with type 2 diabetes is indeed beneficial, 
identifying why patients are not receiving this therapy is an important step in solving the 
issue of underutilization.  
 However, our study also possesses several strengths. Unlike previous research, 
our study adjusted for the number and types of medications when evaluating initiation of 
beta-blockers among this population. This is an important factor in better understanding 
the behavior of both prescribers and patients. Also, cross-validation was conducted to 
show the anticipated predictive power of our model if used with a different dataset in a 
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similar population. Finally, the inclusion of patients with only continuous eligibility and 
at least 6 months of data prior to index MI reduced the likelihood of bias. 
 The predictors identified in our final model set a strong foundation for future 
investigations of the outcomes associated with the use of beta-blockers in this population. 
If (1) the variables are available and reliable, and (2) the variables are related to the 
outcome of interest, all variables in our final model should be considered for adjustment 
in observational studies examining outcomes related to beta-blocker therapy in this 
population. Our study also confirms the results from previous researchers that beta-
blockers are underutilized in this population. The results from this study could help 
clinicians and policymakers determine if more patients with type 2 diabetes should be 
receiving beta-blocker therapy post-MI and could assist in developing interventions 
targeted to patients less likely to receive this therapy.  
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Figure 1 – Selection of study cohort 
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Table 1 – Cohort characteristics 
Patient characteristics N = 341 
Age (years) 63.3 ± 13.1 
Sex 
 
 
Male 199 (58.4) 
 
Female 142 (41.6) 
Race* 
 
 
White 259 (76.2) 
 
Black 27 (7.9) 
 
Other 54 (15.9) 
College degree† 64 (19.2) 
Annual household income‡ 
 
 
Less than $30,000 56 (17.5) 
 
$30,000 to $74,999 173 (54.1) 
 
$75,000 or More 91 (28.4) 
U.S. Census geographic region 
 
 
Midwest 77 (22.6) 
 
Northeast 31 (9.1) 
 
South 191 (56.0) 
 
West 42 (12.3) 
Comorbidities 
 
 
Congestive heart failure 55 (16.1) 
 
Cardiac arrhythmia 74 (21.7) 
 
Valvular disease 37 (10.9) 
 
Pulmonary circulation disorder 9 (2.6) 
 
Peripheral vascular disorder 51 (15.0) 
 
Hypertension 228 (66.9) 
 
Chronic pulmonary disease 73 (21.4) 
 
Hypothyroidism 49 (14.4) 
 
Renal failure 40 (11.7) 
 
Liver disease 10 (2.9) 
 
Obesity 15 (4.4) 
 
Depression 33 (9.7) 
 
Fluid and electrolyte disorder 49 (14.4) 
Blood glucose testing strips 67 (19.7) 
Number of medications 
 
 
None 62 (18.2) 
 
1 to 5 123 (36.1) 
 
6 or more 156 (45.8) 
Any diabetes medication 165 (48.4) 
Sulfonylurea or meglitinide 63 (18.5) 
Insulin 69 (20.2) 
Antihypertensive medications 
 
 
ACE inhibitor or ARB 111 (32.6) 
 
Calcium channel blocker 31 (9.1) 
 
Diuretic 77 (22.6) 
 
Vasodilator 12 (3.5) 
 
Other antiadrenergic 39 (11.4) 
Statin 
 
130 (38.1) 
Beta-blocker post-MI 167 (49.0) 
Data are means ± SD or N (%). All characteristics 
are pre-MI except beta-blocker exposure. * Adds up 
to 340 due to 1 missing value. † Adds up to 333 due 
to 8 missing values. ‡ Adds up to 320 due to 21 
missing values. 
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Table 2 – Characteristics of new users and non-users of beta-blockers 
Patient characteristics 
New users of 
beta-blockers  
(N = 167) 
Non-users of  
beta-blockers  
(N = 174) P value 
Age (years) 61.1 ± 11.1 65.3 ± 14.5 0.003 § 
Sex 
  
0.021 
 
Male 108 (64.7) 91 (52.3) 
 
 
Female 59 (35.3) 83 (47.7) 
 
Race * 
 
 
0.115 
 
White 131 (78.9) 128 (73.6) 
 
 
Black 8 (4.8) 19 (10.9) 
 
 
Other 27 (16.3) 27 (15.5) 
 College degree † 33 (20.5) 31 (18.0) 0.567 
Annual household income ‡ 
 
 
0.388 
 
Less than $30,000 23 (14.8) 33 (20.0) 
 
 
$30,000 to $74,999 84 (54.2) 89 (53.9) 
 
 
$75,000 or More 48 (31.0) 43 (26.1) 
 U.S. Census geographic region 
 
 
0.075 
 
Midwest 37 (22.2) 40 (23.0) 
 
 
Northeast 22 (13.2) 9 (5.2) 
 
 
South 90 (53.9) 101 (58.1) 
 
 
West 18 (10.8) 24 (13.8) 
 Comorbidities 
 
 
 
 
Congestive heart failure 15 (9.0) 40 (23.0) <0.001 
 
Cardiac arrhythmia 23 (13.8) 51 (29.3) 0.001 
 
Valvular disease 13 (7.8) 24 (13.8) 0.075 
 
Pulmonary circulation disorder 6 (3.6) 3 (1.7) 0.328 || 
 
Peripheral vascular disorder 22 (13.2) 29 (16.7) 0.366 
 
Hypertension 106 (63.5) 122 (70.1) 0.193 
 
Chronic pulmonary disease 28 (16.8) 45 (25.9) 0.041 
 
Hypothyroidism 19 (11.4) 30 (17.2) 0.123 
 
Renal failure 11 (6.6) 29 (16.7) 0.004 
 
Liver disease 6 (3.6) 4 (2.3) 0.535 || 
 
Obesity 7 (4.2) 8 (4.6) 0.855 
 
Depression 11 (6.6) 22 (12.6) 0.059 
 
Fluid and electrolyte disorder 13 (7.8) 36 (20.7) 0.001 
Blood glucose testing strips 36 (21.6) 31 (17.8) 0.385 
Number of medications 
 
 
<0.001 
 
None 19 (11.4) 43 (24.7) 
 
 
1 to 5 76 (45.5) 47 (27.0) 
 
 
6 or more 72 (43.1) 84 (48.3) 
 Any diabetes medication 89 (53.3) 76 (43.7) 0.076 
Sulfonylurea or meglitinide 37 (22.2) 26 (14.9) 0.086 
Insulin 35 (21.0) 34 (19.5) 0.745 
Antihypertensive medications 
 
 
 
 
ACE inhibitor or ARB 64 (38.3) 47 (27.0) 0.026 
 
Calcium channel blocker 21 (12.6) 10 (5.8) 0.028 
 
Diuretic 48 (28.7) 29 (16.7) 0.008 
 
Vasodilator 5 (3.0) 7 (4.0) 0.606 
 
Other antiadrenergic 20 (12.0) 19 (10.9) 0.759 
Statin 
 
69 (41.3) 61 (35.1) 0.234 
Data are means ± SD or N (%). All characteristics are pre-MI except beta-blocker exposure. All P 
values based on chi-square statistic except where denoted. * Adds up to 340 due to 1 missing value. 
† Adds up to 333 due to 8 missing values. ‡ Adds up to 320 due to 21 missing values. § Two-sample 
t-test statistic. || Fisher’s exact test statistic. 
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Table 3 – Multivariable logistic regression model 
predicting initiation of beta-blocker after myocardial 
infarction among patients with type 2 diabetes 
Patient characteristics Adjusted OR (95% CI) 
Age 0.98 (0.96–1.00) 
Male 1.50 (0.91–2.47) 
Black* 0.44 (0.16–1.19) 
Congestive heart failure 0.45 (0.21–0.96) 
Cardiac arrhythmia 0.44 (0.23–0.86) 
Depression 0.50 (0.22–1.17) 
Fluid and electrolyte disorder 0.48 (0.21–1.13) 
Renal failure 
 
 
No diuretic 0.17 (0.05–0.65) 
 
Taking a diuretic 1.42 (0.35–5.86) 
Number of medications 
 
 
None Referent 
 
1 to 5 3.59 (1.74–7.38) 
 
6 or more 1.46 (0.70–3.05) 
Calcium channel blocker 2.63 (1.05–6.60) 
All characteristics are pre-MI except beta-blocker exposure. All 
variables from Table 2 were included in initial model except 
college degree, pulmonary circulation disorder, liver disease, 
and obesity. In the initial model, vasodilator and other 
antiadrenergic were combined into other antihypertensive 
category. For race, 1 patient with a missing value was placed in 
the “Other” category. For annual household income, 21 patients 
with missing values were placed in $30,000 to $74,999 category. 
*Based on the results before inclusion of interactions terms, the 
variable for race was changed to a variable indicating whether 
the patient was black. 
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